3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lung Neoplasms
5
Triple Negative Breast Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Camurati-Engelmann Syndrome
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Microsatellite Instability
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Pemetrexed
15
Cisplatin
13
pembrolizumab
6
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cediranib
3
Radiotherapy
3
Gemcitabine
3
Carboplatin
3
amatuximab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Everolimus
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
sodium thiosulfate
1
sargramostim
1
nintedanib
1
napabucasin
1
methoxyamine
1
liposomal doxorubicin
1
incomplete Freund's adjuvant
1
fresolimumab
1
durvalumab
1
defactinib
1
cixutumumab
1
bintrafusp alfa protein, human
1
bemcentinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma, Malignant
×
bintrafusp alfa protein, human
×
Clear all
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts